Low dose methods for treating disorders in which TNFalpha activity is detrimental

• 收藏
• 分享

专利权人:

ABBOTT BIOTECHNOLOGY LTD.

发明人:

KAMEN, ROBERT,KAYMAKCALAN, ZEHRA

申请号：

NZ59694503

公开号：

NZ596945A

申请日:

2003.10.24

申请国别(地区):

NZ

年份:

2013

代理人:

摘要：

NZ 596945 Disclosed is the use of a human anti-TNF-alpha antibody, which is either D2E7 or a human anti-TNF-alpha antibody with equivalent properties to D2E7 which dissociates from human TNF-alpha with a Kd of 1 x 10-8 M or less and a koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, and neutralises human TNF-alpha cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less, for manufacture of a medicament for the treatment of rheumatoid arthritis in a subject, wherein the medicament is to be administered in a low dose of 0.01-0.11 mg anti-TNF-alpha antibody/kg subject in combination with methotrexate.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/